A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

PURPOSE: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases...

全面介紹

Na minha lista:
書目詳細資料
發表在:Leuk Res
Main Authors: Sweet, Kendra, Hazlehurst, Lori, Sahakian, Eva, Powers, John, Nodzon, Lisa, Kayali, Fadi, Hyland, Kelly, Nelson, Ashley, Pinilla-Ibarz, Javier
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787269/
https://ncbi.nlm.nih.gov/pubmed/30340199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.10.002
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍